Three major breakthroughs in the management of neovascular age-related macular degeneration (AMD) have transformed clinical retina practice during the past 25 years: optical coherence tomography (OCT), antioxidant supplements, and anti-VEGF treatment. The introduction of OCT allows physicians to visualize the retinal pathoanatomy and to quantitatively and qualitatively assess disease state and treatment responses. AREDS and AREDS2 showed that specific dietary supplements can moderately reduce vision loss and progression to neovascular disease in high risk dry AMD eyes.\(^1,2\)

The third breakthrough, and perhaps the most important, was the advent of anti-VEGF therapy. Anti-VEGF therapy reduces vision loss by 41% and the onset of severe vision loss and blindness by 46% compared with previous treatment methodologies.\(^3\) Rather than simply slowing down the inevitable decline toward blindness, anti-VEGF therapy for the first time enabled retina specialists to actually restore sight for many patients. The key to visual success is early intervention, as visual outcomes correlate highly with patients’ level of vision when treatment commences; baseline visual acuity at the initiation of anti-VEGF therapy predicts 1-year visual outcomes.\(^4\)

Eyes with neovascularization that is detected early and that receive prompt treatment with anti-VEGF therapy have a high probability of maintaining 20/40 or better vision. For patients, this means they can read, drive, and continue to function independently.

**AT-HOME MONITORING**

Patients with dry AMD have no universal timeline for disease progression. Typically, patients are sent home with an Amsler grid and told to return in 6 months, or earlier if they notice any changes in their vision. Unfortunately, the Amsler grid is not a highly sensitive testing tool.\(^5\) Although some patients experience no change in disease progression over a 6-month period, others may develop changes in pathology that remain undetected and asymptomatic until their next appointment. By the time changes are detected, these eyes may already have significant, irreversible vision loss.

What has been lacking is an effective at-home means of detecting changes in vision related to neovascular AMD. Preferential hyperacuity perimetry (PHP; ForeseeHome; Notal Vision) is a patented technology that detects visual field defects by measuring 500 retinal data points over 14° of a patient’s central visual field. Each data point is measured 3 to 5 times in approximately 3 minutes, and the test has a sensitivity of more than 80% with a very low rate of false-positives.\(^6\)

The ForeseeHome device tests hyperacuity, or Vernier acuity, which is the ability to recognize differences in the spatial location of objects. During a test, users receive visual stimuli consisting of a series of dots, some of which are purposely misaligned, in various locations of the visual field; the patient’s task is to identify the location of the distortion. When the stimuli are projected onto an unhealthy part of the retina, the patient will perceive 2 or more distortions on the line, with 1 corresponding to the artificial wave and the other to the patient’s pathology. Owing to the preferential looking principle, patients will perceive the pathologic distortion more strongly if it is in fact larger than the artificial wave. The patient will then,

"Eyes with neovascularization that is detected early and that receive prompt treatment with anti-VEGF therapy have a high probability of maintaining 20/40 or better vision."
in turn, mark the location of the perceived pathologic wave, thus giving clues as to the location and quantity of underlying pathology. The device has demonstrated an ability to detect changes in users’ visual perceptions often before the patient is aware of them visually.

**HOME STUDY RESULTS**

The Home Monitoring of the Eye (HOME) study was a substudy of the National Eye Institute (NEI)-supported AREDS2. The HOME study evaluated whether detecting neovascular AMD with the ForeseeHome PHP device improved patient outcomes compared with detection with standard care. For the study, 1520 AREDS category 3 and 4 dry AMD patients were enrolled at 44 clinical centers. All eyes had BCVA of 20/60 or better at baseline. Participants were given instructions to test their eyes several times each week with either the ForeseeHome device or using standard care home testing specific for each clinic. Often standard care involved Amsler grid testing.

In the primary analysis of the study, frequent users of the ForeseeHome device showed a median loss of visual acuity of 3.0 ETDRS letters from baseline to neovascular AMD detection, compared with a median loss of 9.0 letters in the standard care cohort. In addition, 94% of patients using the Foresee device to detect conversion to wet AMD maintained 20/40 or better visual acuity at the time of wet AMD detection, compared with 62% of patients using other detection methods.

When reviewing an interim analysis of the study, conducted at approximately 80% of the planned sample study, the study’s independent data safety and monitoring committee noted such a significant difference between using the ForeseeHome device and standard care alone that it recommended the HOME study be terminated early for efficacy.

**PERSONAL EXPERIENCE**

I have been offering ForeseeHome testing to patients for several years and can confirm the study findings. All patients taking AREDS supplements are at high risk for vision loss and are excellent candidates for the Foresee device. I explain to them how the device works and the probability that this technology will best enable them to maintain functional vision so that they can stay independent, read, drive, and see their grandchildren. While there is a modest cost involved, patients generally find this investment in their visual future to be reasonable when compared with the cost of losing their functional sight.

The ForeseeHome device includes telemonitoring that effectively combats poor compliance and dropout. Whenever a change in visual field is detected, the physician’s office is notified immediately so that the patient can be called in for a formal examination. Additionally, the physician is sent monthly reports showing exactly when and how often patients test their visual fields with the device. The manufacturer of ForeseeHome will contact the patient if too many days lapse between tests or if the test is being performed incorrectly. If the company is not successful at encouraging the patient to use the device, the practice is notified so that it can intervene.

In my practice, when patients come in for their examinations, I review the ForeseeHome results to date with them. I show them a graph depicting their frequency of use and give encouragement when needed. Patients tend to think they are more compliant than they actually are.
Showing them the actual data can provide great motivation for improvement.

**CONCLUSION**

Other alternatives to the Amsler grid have been proposed for detecting neovascular AMD, but the ForeseeHome device is the only 1 that has been clinically proven to improve early wet AMD detection with level 1 evidence provided by a large randomized clinical trial.

For me, the Foresee system is the equivalent of going into a patient’s home 3 or 4 times a week and examining him or her, without the invasiveness or the use of scarce resources. I have received alerts of changes in visual field for patients who were examined in my office as recently as 1 week previously (Figure). Amazingly, when we conducted the immediate follow-up, we found pathology that was not present at the previous appointment just a week prior. Their vision was still excellent and they were asymptomatic. We were able to begin treatment immediately and preserve these patients’ vision.

There is still more to be done when it comes to understanding and treating AMD, but the early detection provided by the Foresee device is a breakthrough in AMD treatment. The safety net afforded by the Foresee system closes the loop with recent diagnostic and therapeutic advances in treating wet AMD, allowing patients to achieve the best possible visual results through earlier detection of wet AMD.

Michael J. Elman, MD, is an assistant professor of ophthalmology at the Johns Hopkins University School of Medicine; the director of retina surgery at Franklin Square Hospital; and the founder of the Elman Retina Group, all in Baltimore, Maryland. He is a consultant to Genentech/Roche and Ohr Pharmaceuticals; a speaker for Scienomics; has equity interest in Ohr Pharmaceuticals; and receives research support from Genentech/Roche, Jaeb Center, Merck, National Eye Institute, and XCover Laboratories. Dr. Elman may be reached at elman@elmanretina.com.